Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.

Name: Αlpha¹ Rigor Record — Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.
Item: Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.
Rating: 100
Author: Αlpha¹

Asante KP, Mathanga DP, Milligan P, Akech S, Oduro A, Mwapasa V, Moore KA, Kwambai TK, Hamel MJ, Gyan T, Westercamp N, Kapito-Tembo A, Njuguna P, Ansong D, Kariuki S, Mvalo T, Snell P, Schellenberg D, Welega P, Otieno L, Chimala A, Afari EA, Bejon P, Maleta K, Agbenyega T, Snow RW, Zulu M, Chinkhumba J, Samuels AM, Malaria Vaccine Programme Evaluation Partners

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4★ (Strong), 0 critical, 3 high issues for “Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4 / 5

Strong — minor issues to address

Observational Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced2 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-designed observational evaluation of RTS,S vaccine introduction, with strong scientific premise, robust methods, and transparent reporting. Minor gaps include lack of explicit reporting guideline, incomplete specification of diagnostic reagents, and some internal inconsistencies in numbers.

Both reviewers classified the study as observational; no divergence. The evaluation is a cluster-randomized implementation study using surveillance data, not a controlled trial. Non-applicable sub-criteria (e.g., blinding, cell lines) were excluded. The statistics verification covered only 2 tests; other statistics were not machine-verified.

5 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction and 'Research in context' section cite prior trials and systematic reviews, acknowledge the strengths and weaknesses of the phase 3 trial (including safety signals), and provide a logical rationale for the pilot evaluation. The limitations of prior research (e.g., safety signals, uncertainty about fourth dose) are explicitly addressed as the motivation for this study.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research, including the phase 3 trial and systematic reviews, and clearly links the rationale to the study objectives.

Evidence

direct quote[Introduction, Research in context]

“We identified 25 publications describing data from 14 trials, including one large, multicentre, phase 3 trial. All the trials found that RTS,S/AS01 E had a satisfactory safety profile but, in the multicentre phase 3 trial, there were three safety signals—an excess of meningitis and cerebral malaria cases in RTS,S/AS01 E recipients, and, among girls, more deaths in those who received RTS,S/AS01 E than in controls.”